Barclays initiated coverage of Arvinas (ARVN) with an Overweight rating and $16 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas and Pfizer’s FDA Nod for Cancer Drug
- Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA
- Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating
- Arvinas price target raised to $24 from $18 at H.C. Wainwright
- Arvinas price target lowered to $16 from $19 at Wells Fargo